Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Imatinib Mesylate and Zoledronic Acid in Patients With Chronic Myeloid Leukaemia in Cytogenetic Response Without Molecular Response (AFR22)

This study has been terminated.
Sponsor:
Collaborator:
Novartis
Information provided by:
Institut Bergonié
ClinicalTrials.gov Identifier:
NCT00210119
First received: September 12, 2005
Last updated: July 25, 2013
Last verified: October 2007
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: October 2007
  Estimated Primary Completion Date: No date given